Results 61 to 70 of about 521,269 (357)

Immunomodulatory functions of type I interferons [PDF]

Nature Reviews Immunology, 2012
Interferon-α (IFNα) and IFNβ, collectively known as type I IFNs, are the major effector cytokines of the host immune response against viral infections. However, the production of type I IFNs is also induced in response to bacterial ligands of innate immune receptors and/or bacterial infections, indicating a broader physiological role for these ...
González Navajas, José Manuel, Lee, Jongdae, David, Michael, Raz, Eyal   +3 more
openaire   +3 more sources

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Senegalese sole (Solea senegalensis) ISG15: molecular characterization and in vivo interplay with viral infections [PDF]

, 2015
The interferon-stimulated gene 15 (Isg15) is strongly induced by type I interferon (IFN I), viral infection, and double-stranded RNA (poly I:C) in several fish species, suggesting that Isg15 protein could play a key role in fish innate immunity against ...
Alonso-Sanchez, Maria del Carmen, Bandín, Isabel, Bejar-Alvarado, Julia, García-Rosado, Esther, Podadera, Ana María, Álvarez-Torres, Daniel   +5 more
core  

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome [PDF]

, 2013
Objective: To establish an easy and practical assay for identifying systemic interferon (IFN) type I bioactivity in patients with primary Sjögren's syndrome (pSS).
Brkic, Z. (Zana), Daele, P.L.A. (Paul) van, Dalm, V.A.S.H. (Virgil), Drexhage, H.A. (Hemmo), Heezen, K. (Kim), Helden-Meeuwsen, C.G. (Cornelia) van, Maria, N.I. (Naomi), Merwe, J.P. (Joop) van de, Versnel, M.A. (Marjan), Waris, M. (Matti)   +9 more
core   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Central Role of ULK1 in Type I Interferon Signaling

Cell Reports, 2015
We provide evidence that the Unc-51-like kinase 1 (ULK1) is activated during engagement of the type I interferon (IFN) receptor (IFNR). Our studies demonstrate that the function of ULK1 is required for gene transcription mediated via IFN-stimulated ...
Diana Saleiro, Swarna Mehrotra, Barbara Kroczynska, Elspeth M. Beauchamp, Pawel Lisowski, Beata Majchrzak-Kita, Tushar D. Bhagat, Brady L. Stein, Brandon McMahon, Jessica K. Altman, Ewa M. Kosciuczuk, Darren P. Baker, Chunfa Jie, Nadereh Jafari, Craig B. Thompson, Ross L. Levine, Eleanor N. Fish, Amit K. Verma, Leonidas C. Platanias   +18 more
doaj   +1 more source

Investigation of type I interferon responses in ANCA-associated vasculitis

Scientific Reports, 2021
Type I interferon (IFN) dysregulation is a major contributory factor in the development of several autoimmune diseases, termed type I interferonopathies, and is thought to be the pathogenic link with chronic inflammation in these conditions.
Isabella Batten, Mark W. Robinson, Arthur White, Cathal Walsh, Barbara Fazekas, Jason Wyse, Antonia Buettner, Suzanne D’Arcy, Emily Greenan, Conor C. Murphy, Zoe Wigston, Joan Ní Gabhann-Dromgoole, Edward M. Vital, Mark A. Little, Nollaig M. Bourke   +14 more
doaj   +1 more source

Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. [PDF]

, 2019
The bacterium Mycobacterium tuberculosis (Mtb) causes tuberculosis and is responsible for more human mortality than any other single pathogen1. Progression to active disease occurs in only a fraction of infected individuals and is predicted by an ...
Chen, Katherine J, Darwin, K Heran, Ji, Daisy X, Kramnik, Igor, Mukaida, Naofumi, Vance, Russell E, Yamashiro, Livia H   +6 more
core  

Microarray analyses demonstrate the involvement of type i interferons in psoriasiform pathology development in D6-deficient mice [PDF]

, 2013
The inflammatory response is normally limited by mechanisms regulating its resolution. In the absence of resolution, inflammatory pathologies can emerge, resulting in substantial morbidity and mortality.
Baldwin, H.M., Carballido, J.M., Graham, G.J., Jamieson, T., Jaritz, M., King, V., McKimmie, C.S., Nibbs, R.J.B., Pallas, K., Rot, A.   +9 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source